METHODS FOR MULTIPLEX ANALYTE DETECTION AND QUANTIFICATION

• US 20110306511A1
• Filed: 12/29/2009
• Published: 12/15/2011
• Est. Priority Date: 12/29/2008
• Status: Abandoned Application

• Current Assignee: SQI Diagnostics Systems Inc. (SQI Diagnostics, Inc.)
• Original Assignee: SQI Diagnostics Systems Inc. (SQI Diagnostics, Inc.)
• Inventors: Lea, Peter
• Application Number:
  US12/998,991
• Publication Number:
  US 20110306511A1
• Time in Patent Office: Days
• US Class Current: 506/9
• CPC Class Codes: B01L 3/5085 for multiple samples, e.g. microtitration plates
• CPC Class Codes: G01N 33/543 with an insoluble carrier for immobilising immunochemicals
• CPC Class Codes: G01N 33/564 for pre-existing immune complex or autoimmune disease , i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9

Abstract

The application refers to a method for detecting and quantifying multiple target analytes in a test sample using a single reaction vessel. The method uses a reaction vessel (a multi-well plate), which comprises a microarray of: (a) calibration spots, each having a predetermined quantity of the target analyte; and (b) capture spots, each having an agent (antibody) that selectively binds the target analyte. The captured analytes and the calibration spots are detected with fluorescently labelled antibodies specific for each different target analyte. The calibration spots are used to generate calibration curves that allow the measurement of the concentration of the different target analytes. The application also refers to a method for detecting and quantifying biomarkers that are useful for diagnosing rheumatoid arthritis. More specifically, the application discloses the use of rheumatoid factor (RF) and cyclic citrullinated peptide (CCP), as capture spots. Finally, based on the above method, it is proposed a method for diagnosing or monitoring rheumatoid arthritis.

Claims

1. A method for detecting and quantifying two or more target analytes in a test sample, the method comprising:

a) providing a reaction vessel having a microarray printed thereon, said microarray comprising;

i) a first calibration matrix comprising a plurality of first calibration spots, each calibration spot comprising a predetermined amount of a first target analyte,

ii) a second calibration matrix comprising a plurality of second calibration spots, each calibration spot comprising a predetermined amount of a second target analyte,

iii) a first capture matrix comprising a plurality of first capture spots, each capture spot comprising a predetermined amount of an agent which selectively binds to a first target analyte, and

iv) a second capture matrix comprising a plurality of second capture spots, each capture spot comprising a predetermined amount of an agent which selectively binds to a second target analyte;

b) applying a predetermined volume of the test sample to the microarray;

c) applying a first fluorescently labelled antibody that selectively binds to the first target analyte and a second fluorescently labelled antibody that selectively binds to the second target analyte to the assay device, wherein said first and second fluorescently labelled antibodies each comprise a different fluorescent dye having emission and excitation spectra which do not overlap with each other;

d) measuring a signal intensity value for each spot within the microarray;

e) generating calibration curves by fitting a curve to the measured signal intensity values for each of the calibration spots versus the known concentrations of the first target analyte and second target analyte; and

determining the concentration for the first target analyte and the second target analytes utilizing the generated calibration curves.

2. The method according to claim 1, wherein the target analytes are proteins.

3. The method according to claim 2, wherein the proteins are antibodies.

4. The method according to claim 3, wherein the reaction vessel is a well of a multi-well plate and wherein each well has the microarray printed therein.

5. The method according to claim 1 wherein the test sample is a biological sample.

12. The method according to claim 2, wherein the test sample is a biological sample.

13. The method according to claim 3, wherein the test sample is a biological sample.

14. The method according to claim 4, wherein the test sample is a biological sample.

6. A method for detecting and quantifying biomarkers diagnostic for rheumatoid arthritis, the method comprising:

a) providing an assay device having a microarray printed thereon, said microarray comprising;

i) a calibration matrix comprising a plurality of spots, each spot comprising a predetermined amount of one of;

a human IgA antibody, a human IgG antibody, and a human IgM antibody;

ii) a first analyte capture matrix comprising a plurality of spots comprising a predetermined amount of rheumatoid factor; and

iii) a second analyte capture matrix comprising a plurality of spots comprising a predetermined amount of cyclic citrullinated peptide;

b) applying a predetermined volume of a serum sample to the assay device;

c) applying a first fluorescently labelled antibody which selectively binds to IgA antibodies, a second fluorescently labelled antibody which selectively binds to IgG antibodies, and a third fluorescently labelled antibody which selectively binds to IgM antibodies to the assay device, wherein said first, second and third fluorescently labelled antibodies each comprise a different fluorescent dye having emission and excitation spectra which do not overlap with each other;

d) measuring a signal intensity value for each spot within the assay device;

e) generating calibration curves by fitting a curve to the measured signal intensity values for the each of the calibration spots versus the known concentration of the human IgA, IgG and IgM antibodies; and

f) determining the concentration for each of captured rheumatoid factor-IgA, rheumatoid factor-IgG, rheumatoid factor-IgM, anti-cyclic citrullinated peptide-IgG, anti-cyclic citrullinated peptide-IgA, and/or anti-cyclic citrullinated peptide-IgM using utilizing the calibration curves;

7. A method for diagnosing rheumatoid arthritis in a subject, the method comprising:

a) measuring the concentration levels of rheumatoid factor-IgA, rheumatoid factor-IgG, rheumatoid factor-IgM and at least one of anti-cyclic citrullinated peptide-IgG, anti-cyclic citrullinated peptide-IgA, and anti-cyclic citrullinated peptide-IgM in a biological sample, utilizing the method according to claim 6; and

b) comparing the measured concentration levels of rheumatoid factor-IgA, rheumatoid factor-IgG, rheumatoid factor-IgM, anti-cyclic citrullinated peptide-IgG, anti-cyclic citrullinated peptide-IgA, and/or anti-cyclic citrullinated peptide-IgM with index normal levels of rheumatoid factor-IgA, rheumatoid factor-IgG, rheumatoid factor-IgM and anti-cyclic citrullinated peptide-IgG, anti-cyclic citrullinated peptide-IgA, and/or anti-cyclic citrullinated peptide-IgM wherein measured concentrations levels which exceed index normal levels is diagnostic for rheumatoid arthritis.

8. The method of claim 7, wherein detection and quantification of predominantly rheumatoid factor-IgM and anti-cyclic citrullinated peptide-IgM antibodies is diagnostic for an early stage of rheumatoid arthritis.

9. The method of claim 7, wherein the detection and quantification of rheumatoid factor-IgA and anti-cyclic citrullinated peptide-IgA antibodies is diagnostic for a transitional stage of rheumatoid arthritis.

10. The method of claim 7, wherein the detection and quantification of rheumatoid factor-IgG and anti-cyclic citrullinated peptide-IgG antibodies is diagnostic for a late stage of rheumatoid arthritis.

11. The method according to claim 6, further comprising monitoring rheumatoid arthritis treatment in a subject suffering therefrom by:

measuring the concentration levels of rheumatoid factor-IgA, rheumatoid factor-IgG, rheumatoid factor-IgM, and at least one of anti-cyclic citrullinated peptide-IgG, anti-cyclic citrullinated peptide-IgA, and anti-cyclic citrullinated peptide-IgM, a plurality of times during the treatment.